ReciBioPharm signed a collaboration agreement with GeneVentiv Therapeutics, a preclinical gene therapy company, to advance the development of an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, and reportedly the first to treat hemophilia patients with inhibitors.
GeneVentiv’s GENV-HEM (AAV8.FVa) is a single infusion, universal AAV-based gene therapy for all types of hemophilia and has demonstrated therapeutic efficacy and safety in preclinical studies, notes Damon Race, CEO of GeneVentiv. ReciBioPharm plans to accelerate the development of this technology using its AAV manufacturing platform at its Watertown facility in Massachusetts.
“Gene therapies pose unique development and manufacturing challenges, so it was essential we chose the right partner to collaborate with, to minimize manufacturing risks and ensure we meet our key development milestones,” continues Race.
“ReciBioPharm quickly demonstrated that their team is the perfect development and manufacturing partner for our asset, enabling us to access their extensive experience and impressive capabilities. Our collaboration with them provides us with GLP and GMP product to meet both our IND and Phase I/II milestones.”
